As shown in our analysis, four PPAR agonists were more effective than other drugs in reducing ALP biochemical levels as adjunctive therapy for patients with PBC refractory to UDCA, bezafibrate and fenofibrate were second only to elafibranor and saroglitazar. Here, PPARA is linked to primary biliary cholangitis.